# US 2016/0252523 A1 · Method for removing genomically unstable ips cells and synthetic peptide used therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0252523 A1
- Document ID: US20160252523A1
- Status: Published application
- Kind: A1
- Application number: 15/033,452
- Filed: 2014-10-30
- Published: 2016-09-01
- Earliest claimed: 2013-10-30
- Assignees: Toagosei Co., Ltd.; Kyoto University
- Applicants: Toagosei Co., Ltd.; Kyoto University
- Inventors: Tetsuhiko YOSHIDA; Nahoko BAILEYKOBAYASHI; Yoshinori YOSHIDA; Kazuhisa CHONABAYASHI
- Web page: https://patentgrep.com/patent/US20160252523A1

## CPC

- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/4705: {stimulating, promoting or activating activity}
- C07K 14/4725: {Proteoglycans, e.g. aggreccan}
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- G01N 15/14: Optical investigation techniques, e.g. flow cytometry
- G01N 15/1433: using image recognition
- C07K 2319/01: containing a localisation/targetting motif
- C12Q 2600/158: Expression markers
- G01N 15/01: specially adapted for biological cells, e.g. blood cells (investigating sedimentation of particle suspensions in blood G01N15/05)
- G01N 15/149: specially adapted for sorting particles, e.g. by their size or optical properties
- G01N 2015/1006: {for cytology}
- G01N 2015/1488: {Methods for deciding}
- G01N 2333/4703: Regulators; Modulating activity
- G01N 2333/4706: stimulating, promoting or activating activity
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention provides a method that allows highly efficient and highly reliable evaluation of genomic stability of pluripotent stem cells, a method for removing pluripotent stem cells that have been identified as genomically unstable by the evaluation method from a culture of pluripotent stem cells to be evaluated, and a synthetic peptide that can be used for the methods. The methods provided by the present invention include preparing a culture of pluripotent stem cells of interest and analyzing an expression level of calreticulin for the pluripotent stem cells in the culture followed by identifying genomic stability or genomic instability of the stem cells on the basis of the expression level of calreticulin.

## Claims

### Claim 1

A method for evaluating genomic stability of pluripotent stem cells of interest derived from humans or a mammal other than humans, comprising:
preparing a culture of the pluripotent stem cells; and
analyzing an expression level of calreticulin for the pluripotent stem cells in the culture followed by identifying genomic stability or instability of the pluripotent stem cells on the basis of the expression level of calreticulin,
wherein in the identification, pluripotent stem cells, for which the expression level of calreticulin of the stem cells is above a prescribed level, are identified as genomically unstable.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the identification of genomic stability or instability of the pluripotent stem cells based on the expression level of calreticulin is carried out by an immunological assay using an antibody specifically reacting with calreticulin or a fragment thereof.

### Claim 3 (depends on 1)

The method according to claim 1, further comprising, prior to the identification, supplying, at least once, to the pluripotent stem cell culture of interest a synthetic peptide comprising a calreticulin expression inducing peptide sequence consisting of either of the following amino acid sequences:
(SEQ ID NO: 1)
CRAKAGDPC;
and
(SEQ ID NO: 2)
CEQKQEIRC;
or a modified amino acid sequence formed by substitution, deletion or addition of 1, 2 or 3 amino acid residues in/from/to the above amino acid sequences, wherein the identification is carried out after culturing, for a prescribed time, the pluripotent stem cell culture to which the synthetic peptide has been supplied at least once.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the modified amino acid sequence is an amino acid sequence of SEQ ID NO: 1 or 2 from which N-terminal and C-terminal cysteine residues (C) are deleted.

### Claim 5 (depends on 3)

The method according to claim 3, wherein the synthetic peptide comprises a membrane-penetrating peptide sequence N-terminal or C-terminal to the calreticulin expression inducing peptide sequence.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the synthetic peptide comprises the membrane-penetrating peptide sequence consisting of the following amino acid sequence:
(SEQ ID NO: 5)
KKRTLRKNDRKKR.

### Claim 7 (depends on 3)

The method according to claim 3, wherein the synthetic peptide has 30 or less amino acid residues in total.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the synthetic peptide comprised any of the following amino acid sequences:
(SEQ ID NO: 10)
KKRTLRKNDRKKRGGCRAKAGDPC;
(SEQ ID NO: 11)
KKRTLRKNDRKKRGGCEQKQEIRC;
(SEQ ID NO: 12)
KKRTLRKNDRKKRGGRAKAGDP;
and
(SEQ ID NO: 13)
KKRTLRKNDRKKRGGEQKQEIR.

### Claim 9 (depends on 1)

The method according to claim 1, further comprising:
removing the pluripotent stem cells that have been identified as genomically unstable method from the culture of the pluripotent stem cells.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the pluripotent stem cells that have been identified as genomically unstable are removed by using a cell sorter.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the genomically unstable pluripotent stem cells are pluripotent stem cells having a chromosome aberration.

### Claim 12

(canceled)

### Claim 13

An artificially synthesised peptide exhibiting calreticulin expression inducing activity on genomically unstable pluripotent stem cells, the synthetic peptide comprising a calreticulin expression inducing peptide sequence consisting of either of the following amino acid sequences:
(SEQ ID NO: 1)
CRAKAGDPC;
and
(SEQ ID NO: 2)
CEQKQEIRC;
or a modified amino acid sequence formed by substitution, deletion addition of 1, 2 or 3 amino acid residues in/from/to the above amino acid sequences.

### Claim 14 (depends on 13)

The synthetic peptide according to claim 13, wherein the modified amino acid sequence is an amino acid sequence of SEQ ID NO: 1 or 2 from which N-terminal and C-terminal cysteine residues (C) are deleted.

### Claim 15 (depends on 13)

The synthetic peptide according to claim 13, comprising a membrane-penetrating peptide sequence N-terminal or C-terminal to the calreticulin expression inducing peptide sequence.

### Claim 16 (depends on 15)

The synthetic peptide according to claim 15, comprising the membrane-penetrating peptide sequence consisting of the following amino acid sequence:
(SEQ ID NO: 5)
KKRTLRKNDRKKR.

### Claim 17 (depends on 13)

The synthetic peptide according to claim 13, wherein the synthetic peptide has 30 or less amino acid residues in total.

### Claim 18 (depends on 17)

The synthetic peptide according to claim 17, comprising any of the following amino acid sequences:
(SEQ ID NO: 10)
KKRTLRKNDRKKRGGCRAKAGDPC;
(SEQ ID NO: 11)
KKRTLRKNDRKKRGGCEQKQEIRC;
(SEQ ID NO: 12)
KKRTLRKNDRKKRGGRAKAGDP;
and
(SEQ ID NO: 13)
KKRTLRKNDRKKRGGEQKQEIR.

### Claim 19 (depends on 13)

An agent for inducing calreticulin expression used for increasing an expression level of calreticulin in genomically unstable pluripotent stem cells, comprising the synthetic peptide according to claim 13.
